RxDoctor Payments Data

Vernon King, MD

Radiation Oncology · Grand Junction, CONPI 1649278003

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novocure Inc. at 51.9% of the total. Reporting peaked in 2022 at $242 and has fallen 90.4% since, to $23 in 2025. That places this record below the midpoint for radiation oncology clinicians in CO, where the typical reported total is $456.

$479in general payments, 2019–2025

Across 14 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$249
  • E.r. Squibb & Sons, L.L.C.$86
  • Siemens Medical Solutions USA, Inc.$55
  • MIM Software Inc.$39
  • Tactile Systems Technology Inc$23
  • Merck$20
  • plus $9 from 1 others
$54,000in research payments, 2019–2025

Across 3 payments — averaging $18,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$54K

What the payments were for

  • Food & beverage$45996%
  • Education$204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479 in reported general payments places this provider in the 50th percentile of 105 radiation oncology providers in Colorado.

See all radiation oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$76,599
Medicare patients
86
Services billed
743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Megestrol Acetate13$619
Dexamethasone21$251
Lorazepam15$10

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →